APPLICATION OF THYMOSINE-ALPHA-1 FOR PRODUCING A MEDICINE FOR TREATING MALIGNANT MELANOMA IN STAGE IV

摘要

1. The use of thymosin-alpha-1 at a dose of 3.2 or 6.4 mg / day / pc. in combination with dacarbazine to obtain a drug for the treatment of malignant melanoma in stage IV, characterized by distant inoperable metastases. ! 2. The use according to claim 1, wherein dacarbazine is used in a dose of 500 to 1100 mg / m2 / day / iv. ! 3. The use according to claim 1, wherein dacarbazine is used at a dose of 800 mg / m2 / day / iv. ! 4. The use of claim 1, wherein the patients to be treated have a normal serum LDH level. ! 5. A method of treating malignant melanoma in stage IV, comprising administering thymosin-alpha-1 at a dose of 3.2 or 6.4 mg / day / pc. in combination with an effective amount of dacarbazine to a mammal in need of such treatment. ! 6. The method according to claim 5, wherein the malignant melanoma is characterized by distant inoperable metastases. ! 7. A method of treating malignant melanoma in a patient, comprising administering a synergistic combination of thymosin-alpha-1 and dacarbazine to a patient in need thereof, said combination being administered in accordance with a regimen in which dacarbazine is administered on day 1 and thymosin-alpha-1 is administered within about one to two weeks after dacarbazine administration. !eight. The method of claim 5, wherein the patients to be treated have a normal serum LDH level. ! 9. A kit for treating malignant melanoma containing thymosin-alpha-1 and dacarbazine, wherein said thymosin-alpha-1 is present in an amount sufficient to administer a daily dose of 3.2 or 6.4 mg / bp, dacarbazine is present in an amount sufficient to administer a daily dose of at least 500 mg / m2 / day / iv.